| Followers | 59 |
| Posts | 7590 |
| Boards Moderated | 0 |
| Alias Born | 10/20/2014 |
Friday, September 10, 2021 6:30:24 AM
Zip, Agree 100%. Any BP at anytime could initiate discussions with
AMRN or even make a hostile bid. The Pfizer/HLS deal at a minimum shows
that at least Vascepa is on Pfizer's radar, and should make any other BP
that is remotely interested in AMRN nervous that they could have competition. Of course Pfizer is not going to tell HLS that they
may be interested ultimately in a BO of AMRN, even if they were,
because they would not want to tip their hand. The idea that Pfizer
is only doing this so their Cardio reps can be selling a CVD product is
plausible as a public reason for Pfizer's move. Meowza is correct that
Pfizer has a ton of goodwill in Europe (and of course the US) with its
vaccine being regarded as safe and effective. Imagine what Pfizer could
do with Vascepa for CVD. Pfizer could even claim that they know that
Vascepa not only reduces the risk of events from CVD, but its mode of
action may help to resolve residual inflammation either from the
vaccine or COVID-19 itself, (assuming that is proven.) Vascepa could
be a mega-blockbuster for Pfizer "if" they want it!
AMRN or even make a hostile bid. The Pfizer/HLS deal at a minimum shows
that at least Vascepa is on Pfizer's radar, and should make any other BP
that is remotely interested in AMRN nervous that they could have competition. Of course Pfizer is not going to tell HLS that they
may be interested ultimately in a BO of AMRN, even if they were,
because they would not want to tip their hand. The idea that Pfizer
is only doing this so their Cardio reps can be selling a CVD product is
plausible as a public reason for Pfizer's move. Meowza is correct that
Pfizer has a ton of goodwill in Europe (and of course the US) with its
vaccine being regarded as safe and effective. Imagine what Pfizer could
do with Vascepa for CVD. Pfizer could even claim that they know that
Vascepa not only reduces the risk of events from CVD, but its mode of
action may help to resolve residual inflammation either from the
vaccine or COVID-19 itself, (assuming that is proven.) Vascepa could
be a mega-blockbuster for Pfizer "if" they want it!
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
